The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Neoadjuvant ipilimumab in locally/regionally advanced melanoma: Clinical outcome and immune monitoring.
Ahmad A. Tarhini
Consultant or Advisory Role - Prometheus; Roche/Genentech
Research Funding - Bristol-Myers Squibb
Howard Edington
No relevant relationships to disclose
Lisa H. Butterfield
No relevant relationships to disclose
Hussein Tawbi
No relevant relationships to disclose
Stergios J. Moschos
No relevant relationships to disclose
Yongli Shuai
No relevant relationships to disclose
Yan Lin
No relevant relationships to disclose
Mary Horak
No relevant relationships to disclose
Saro Sarkisian
No relevant relationships to disclose
Janice Shipe-Spotloe
No relevant relationships to disclose
Christy Milburn
No relevant relationships to disclose
Cindy Sander
No relevant relationships to disclose
Jonas Talmadge Johnson
No relevant relationships to disclose
John M. Kirkwood
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - Merck